Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout

Xconomy San Francisco — 

Gilead Sciences is acquiring Immunomedics in a $21 billion deal, the latest in a string of transactions the company has made to bolster its cancer drug portfolio.

The acquisition announced Sunday comes five months after Morris Plains, NJ-based Immunomedics won FDA approval for cancer drug sacitizumab govitecan (Trodelvy). The regulatory decision covers triple negative breast cancer but the drug, projected to become a blockbuster seller, is also being evaluated in other types of cancer.

According to deal terms announced Sunday, Foster City, CA-based Gilead (NASDAQ: GILD) has agreed to pay $88 cash per share of Immunomedics (NASDAQ: IMMU), a 108 percent premium to the stock’s closing price on Friday. In its announcement, Gilead describes the Immunomedics drug as a “cornerstone product” that adds to the company’s pipeline of drugs for solid tumors. The company also says the drug will complement its approved drugs and those still in the pipeline for treating blood cancers.

Sacitizumab govitecan is a type of targeted therapy called an antibody drug conjugate (ADC). It hitches a powerful cancer-killing compound to a targeting antibody providing a direct strike to tumors that spares healthy cells. ADCs aren’t new but the Immunomedics drug is the first one approved to hit Trop 2, a protein on the surface of the cells of many solid tumors.

Sacitizumab govitecan was approved for treating triple-negative breast cancer in patients whose disease has not responded to two earlier treatments and has spread. Immunomedics has estimated between 8,000 and 9,000 patients fit those criteria. The April approval was an accelerated decision based on a single Phase 2 study. The company launched the drug in May.

A Phase 3 study evaluating the drug stopped early after an independent monitoring committee unanimously concluded that the data demonstrated efficacy. Those data are expected to be presented at the year’s European Society for Medical Oncology Virtual Congress 2020, which is starting Saturday. Immunomedics expects to file for full FDA approval of the drug in the fourth quarter of this year. A regulatory decision in Europe is expected in the first half of next year.

The Immunomedics drug is also being evaluated in a Phase 3 study as a third choice treatment in HR positive and HER2 negative breast cancer, as well as a Phase 2 study in bladder cancer that is expected to be sufficient to support a regulatory submission. Other studies are evaluating the drug in non-small cell lung cancer and other types of solid tumors. Gilead says it plans to start additional mid- and late-stage studies soon to assess which patients will benefit from sacitizumab govitecan by itself and which patients can be helped by the drug in combination with other therapies.

Gilead has been an active dealmaker this year, with a particular focus on striking deals with cancer drug developers. The Immunomedics acquisition announcement comes two weeks after the company reached a $120 million deal for rights to an antibody drug from Jounce Therapeutics (NASDAQ: JNCE) that is approaching clinical testing. Earlier this summer, Gilead took large equity stakes in Pionyr Immunotherapeutics and Tizona Therapeutics. The dealmaking spree started in March, with an agreement to pay $4.9 billion for Forty Seven.

The Immunomedics acquisition will take place in two steps. In the first step, Gilead will make a tender offer to acquire all of the outstanding shares of Immunomedics. After that offer is completed, the next step calls for Gilead to acquire the remaining shares. Those shares will be purchased at the same price as those acquired in the tender offer. Gilead says it will finance the buyout with $15 billion in cash on hand and $6 billion in debt. The boards of directors of both companies have approved the acquisition, which is expected to close the deal in the fourth quarter of this year. According to a Gilead securities filing, Immunomedics has agreed not to seek out better offers. But if an unsolicited bid comes in to top Gilead’s offer and the Immunomedics board selects it as the superior offer, the New Jersey company would owe Gilead a $732.1 million termination fee.

Image: iStock/Darrin Hughes

 

Want more Xconomy content? Subscribe today for free newsletters, event and webinar alerts, whitepapers, podcasts, and more.